



May 11th, 2022

Medical Directors  
MoIDX Program  
Palmetto GBA, LLC  
17 Technology Circle  
Columbia, SC 29203

Re: New LCD Request

Dear MoIDX Program Medical Directors,

We respectfully submit the enclosed request for an LCD concerning molecular biomarkers for decision-making in localized and locally advanced/metastatic renal neoplasms.

The treatment of renal neoplasms is complex, and some tumors may actually represent benign disease. With the availability of multiple treatment options in each clinical scenario for localized renal neoplasms and advanced stage renal cancers, biomarkers to help determine optimal treatment have become important in guiding management decisions. There is a long history of research and development utilizing the Decipher testing platform, and we continue to participate in research to find new strategies to improve care for urologic malignancies with the development and validation of new transcriptomic kidney tumor signatures.

We believe that providing Medicare beneficiaries access to these biomarkers will enable better treatment decisions and will improve patient outcomes.

Thank you for your consideration of this request.

Sincerely,

Elai Davicioni PhD  
Medical director, Urology